PAUL DI FLAURO: Open Payments
NPI 1114400959 · PASADENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,360 in 47 payments from 20 companies in 2025. Trend: 2023 $1,008 · 2024 $1,108 · 2025 $1,360
Food & beverage: $1,160Education: $200
| Company | Payments | Amount |
|---|---|---|
| BeOne Medicines USA, Inc. | 9 | $199 |
| ABBVIE INC. | 5 | $182 |
| Novartis Pharmaceuticals Corporation | 7 | $143 |
| Amgen Inc. | 1 | $125 |
| Stemline Therapeutics Inc. | 1 | $124 |
| Astellas Pharma US Inc | 1 | $100 |
| AstraZeneca Pharmaceuticals LP | 5 | $95 |
| Daiichi Sankyo Inc. | 4 | $83 |
| BeiGene USA, Inc. | 2 | $64 |
| Janssen Biotech, Inc. | 2 | $38 |
Products named: BRUKINSA, SCEMBLIX, KYPROLIS, ELZONRIS, IMBRUVICA, CALQUENCE, Vanflyta, VENCLEXTA.
Industry payments across CA — which companies pay providers there.
